Functional Assessment Of The Preserflo Microshunt Implant In Patients With High Myopia: 2 Years Follow-Up
Published 2025 - 43rd Congress of the ESCRS
Reference: FP22.14 | Type: Free paper | DOI: 10.82333/em31-nj80
Authors: Ivan Gabric* 1 , Francesco Versaci 2 , Karla Bodakoš 1 , Mateja Jagic 1 , Maja Bohač 1
1Refractive surgery,Eye Clinic Svjetlost,Zagreb,Croatia, 2R&D,CSO Italia,Florence,Italy
Purpose
The primary objectives of this study are to assess the reduction in intraocular pressure (IOP) and the decrease in topical hypotensive treatment after a Preserflo surgery in patients with high myopia and open angle glaucoma. Additionally, secondary endpoints include the evaluation of changes in visual acuity, visual field, as well as complications.
Setting
Tertiary hospital within the Spanish National Health System.
Methods
Retrospective evaluation of an institutional cohort of 90 patients who underwent Preserflo implant surgery between July 2020 and December 2022 at our hospital, which serves as a specialized center for managing complex glaucoma cases. For this study, analysis was restricted to patients with glaucoma and high myopia, defined as axial length >26 mm or refractive error >6 diopters, with a follow-up period of at least two years. A total of 18 eyes were finally analized.
Results
Mean IOP was reduced from 19,8 +/- 5,6 mmHg at baseline to 12 (IQR 8-14,8 mmHg) at year 1 (P < 0.001) and to 12,9 +/- 2,5 mmHg at year 2 (P < 0.001). Mean number of glaucoma medications per patient decreased from 2,72 +/- 0,8 at baseline to 0,29+/-0,7 at year 1 (P < 0.001) and to 0 0,47 +/- 0,8 at year 2 (P < 0.001). The median time to reintroduction of topical treatment was 141 days (IQR 75.3–518.8). Overall success was 83,33% at year 1 and 77,7% at year 2. We registered 11 intraoperative hyphema, 1 creation of 2 or more access, 3 numerical hypotony and 1 Seidel as early adverse effects (AE). Regarding late AE, bleb encapsulation was the only AE observed. No choroidal detachment or macular aedema were observed.
Conclusions
Current evidence in the myopic population is scarce due to controversial surgical indications and outcomes. However, our results align with existing data on Preserflo in primary open-angle glaucoma surgeries and trabeculectomy for patients with high myopia, showing no higher rate of adverse events. This supports Preserflo as a safe and effective device for lowering IOP and reducing the need for medications in these patients.